Liraglutide Trial Investigates Postprandial Triglyceride Reduction in Type 2 Diabetes

Type 2 Diabetes (T2DM) is a chronic metabolic disorder characterized by high blood glucose. Beyond glycemic control, managing dyslipidemia, particularly elevated postprandial triglycerides, is crucial due to its strong association with increased cardiovascular disease risk. Current T2DM treatments often target glucose, but specific interventions for postprandial lipid excursions are needed. Liraglutide, a GLP-1 receptor agonist, is known for its glucose-lowering and weight-reducing effects, but its direct impact on postprandial lipid metabolism, independent of its glycemic actions, warrants dedicated investigation.

This randomized, double-blind, crossover Phase 1 clinical trial enrolled 20 subjects with Type 2 Diabetes in Europe. Participants underwent two 3-week treatment periods separated by a 3 to 9-week wash-out. In one period, subjects received escalating doses of liraglutide (one week each of 0.6 mg, 1.2 mg, and 1.8 mg). In the other period, they received placebo for 3 weeks. At the end of each 3-week treatment period, a high-fat meal test was performed to assess postprandial blood lipid levels, including triglycerides and cholesterol, as the primary endpoint.

The provided clinical trial record (NCT00993304) describes the study design and objectives but does not include any results or findings from the trial. The abstract states the aim was to investigate whether liraglutide reduces postprandial lipid levels in Type 2 Diabetes patients. As of the information available, specific data on changes in triglyceride levels, cholesterol, or other lipid parameters following liraglutide treatment compared to placebo are not presented. Therefore, no quantitative outcomes, statistical significances, or effect sizes can be reported from this source.